Elevance Health raises FY 2026 diluted EPS guidance to at least $20.10
Company lifts FY 2026 adjusted diluted EPS guidance to at least $27.00
Elevance Health increases FY 2026 operating cash flow guidance to at least $6.0 bln
Overview
U.S. health insurer's Q2 operating revenue rose 0.8% yr/yr to $49.8 bln
Adjusted EPS for Q2 was $7.45, beating analyst expectations
Company raised full-year 2026 adjusted EPS guidance to at least $27.00
Key details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Revenue
$49.80 bln
Q2 Adjusted EPS
Beat
$7.45
$6.21 (21 Analysts)
Q2 EPS
$6.71
Q2 Benefit Expense Ratio
89.70%
Result Drivers
Premium yields & Carelon growth - Revenue growth was driven by higher premium yields in Health Benefits and increased CarelonRx product revenue, partially offset by declines in Medicare Advantage, Medicaid, and Employer Group risk membership.
Higher medical costs - Benefit expense ratio rose due to elevated medical cost trend in Government businesses, partially offset by improved Individual ACA performance.
Targeted investments - Operating expense ratio increased due to investments in workforce and capabilities to support long-term operating model.
ELV•
